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In 2010, Multilineage Differentiating Stress Enduring (Muse) cells were introduced to the scientific community,
offering potential resolution to the issue of teratoma formation that plagues both embryonic stem (ES) and
induced pluripotent (iPS) stem cells. Isolated from human bone marrow, dermal fibroblasts, adipose tissue and
commercially available adipose stem cells (ASCs) under severe cellular stress conditions, Muse cells self-renew in a
controlled manner and do not form teratomas when injected into immune-deficient mice. Furthermore, Muse
cells express classic pluripotency markers and differentiate into cells from the three embryonic germ layers both
spontaneously and under media-specific induction. When transplanted in vivo, Muse cells contribute to tissue
generation and repair. This review delves into the aspects of Muse cells that set them apart from ES, iPS, and
various reported adult pluripotent stem cell lines, with specific emphasis on Muse cells derived from adipose tissue
(Muse-AT), and their potential to revolutionize the field of regenerative medicine and stem cell therapy.
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Embryonic and induced pluripotent stem cells: the gold
standard
ES cells have unequivocally taken center stage in the
field of stem cell research. Isolated from human blas-
tocysts in the late 20th century, ES cells exhibited the
potential to treat a plethora of previously irreversible
disorders through their capacity to generate tissues of
the three embryonic germlines, and thus to revolutionize
regenerative medicine [1-3]. Their unlimited prolifera-
tion as well as their ability to remain in an undifferen-
tiated state for extended periods of time secured their
position at the forefront of scientific research for over
two decades. However, evidence has since emerged that
ES cells exhibit high rates of immunorejection upon
transplantation and form teratomas as a result of their
unbridled proliferation [4]. In conjunction with debates
surrounding the bioethical issues concerning the usage
of human embryos, this teratogenic propensity precludes* Correspondence: gchazenbalk@mednet.ucla.edu
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in any medium, provided the original work is pthe practical application of ES cells in regenerative
medicine.
In response, iPS cells quickly assumed their position
as the new, fervently pursued subject of interest in
the stem cell field [5,6]. iPS cells are reprogrammable
through the induction of “Yamanaka factors,” including
Nanog, Oct3/4, Sox2, c-Myc and Klf4, and can be uti-
lized autologously, resolving issues of immunorejection
at the time of transplantation [6-9]. While iPS cells
resolve the bioethical concerns surrounding the use of
stem cells extracted from human embryos, the pro-
duction of teratomas as a consequence of uncontrolled
cell proliferation impede the translational application of
these cells for stem cell therapy [10,11]. Furthermore,
mature iPS cells possess an epigenetic memory, wherein
the remnants of posttranslational histone and DNA
modifications prevent complete reprogramming as well
as their physiological function beyond the range of their
cell type of origin [7,12-14]. Investigators have made at-
tempts to address these issues, but to little avail [15,16].
Despite excessive monetary and temporal efforts devoted
to the study of both ES cells and iPS cells, there hasis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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cing these stem cells and their use towards cell therapy.
Adult pluripotent stem cells at a glance
Other, non-reprogrammed pluripotent stem cell popula-
tions have caught the attention of the scientific com-
munity as an alternative to ethically contentious ES cells
and genetically modified iPS cells. However, though
several populations of adult stem cells that possess plu-
ripotency have been put forth, many have faced a great
deal of suspicion due to irreproducibility and pluripo-
tency marker identification. Isolated from bone marrow,
multipotent adult progenitor cells (MAPCs), both plu-
ripotent and non-tumorigenic, were reported to con-
tribute to chimeric offspring when injected into a mouse
model and to regenerate damaged tissue in vivo [17,18].
Human marrow-isolated adult multilineage inducible
(MIAMI) cells and very small embryonic-like stem cells
(VSELs), isolated from umbilical cord blood in addition
to bone marrow, were soon to follow, exhibiting similar
pluripotent and non-tumorigenic properties [17-19].
Like VSELs, unrestricted somatic stem cells (USSCs),
isolated from umbilical cord blood, are reportedly pluri-
potent but lack the classic pluripotent stem cell marker
expression [20]. These adult pluripotent stem cell lines
have all been publically flagged for further investigation
and reproduction, or in the case of VSELs, negated en-
tirely [21,22].
Stimulus-triggered acquisition of pluripotency (STAP),
characterized by exposing splenic CD45+ lymphocytes
to acidic conditions followed by incubation with leukae-
mia inhibitory factor (LIF), has recently been described
as a method of bestowing pluripotency upon somatic
cells [23]. However, STAP cells form teratomas, hinde-
ring their clinical application. STAP cells are currently
under investigation to determine the overall validity of
the published results as well as the mechanism behind
their reprogramming.
The advent of muse cells
In 2010, a research team at the Tohoku University in Sendai,
Japan, identified a population of pluripotent mesenchymal
stem cells (MSCs), named Multilineage Differentiating
Stress Enduring (Muse) cells, through the induction of
severe cellular stress. Initially isolated from bone marrow
aspirates and human skin fibroblasts, this cell population
expresses the pluripotency marker stage-specific embryonic
antigen-3 (SSEA-3) as well as the mesenchymal cell marker
CD105 [24,25]. Our research team at the University of
California, Los Angeles, discovered that Muse cells exist in
human adipose tissue as well [26]. Imposing alternate, yet
comparably high stress conditions, we isolated Muse cells,
derived from adipose tissue harvested by lipoaspiration
(Muse-AT cells) [26]. More recently, investigators haveshown that Muse cells can be isolated from commercially
available human adipose stem cells (ASCs) through SSEA-3
cell sorting as well [27]. Much like their relatives derived
from bone marrow aspirates and skin fibroblasts [24],
Muse-AT cells form cell clusters similar to ES cells when
grown in suspension. Muse-AT cells also express the classic
pluripotency markers SSEA3, Sox2, Oct3/4, Nanog and
TRA1-81 [24,26].
Pluripotency of muse cells in vitro and in vivo
Muse cells grow in suspension as cell clusters reminiscent
of embryonic stem cells. Muse cells intrinsically express
classic pluripotency markers including SSEA3, Nanog,
Oct3/4, Sox2, TRA1-60 and TRA1-81 [24,26]. Further-
more, Muse cells, both spontaneously and under specific
culture conditions, express mesodermal (α-smooth muscle
actin, desmin, DLK, Bodipy and myosin D), endodermal
(α-fetoprotein, cytokeratin 7, GATA6 and pan keratin),
and ectodermal (neurofilament-M, MAP2, Glut-R, and
NeuroD) markers [24,26]. Intravenously administered
GFP-labeled human Muse cells injected into damaged
skin, muscle, and liver tissue of immunodeficient mice
were able to integrate and differentiate accordingly in vivo
and contribute vastly to tissue regeneration within 2–4
weeks [24]. Human Muse cells were successfully applied
in models of fulminant hepatitis, muscle degeneration and
skin injury in different mouse-disease models [21].
Muse cells, induced to grow into 3D cultured skin
in vitro, have the capacity to give rise to mature melano-
cytes, contributing to tissue regeneration after engraftment
into damaged skin [28]. The authenticity of Muse-derived
melanocytes is supported both molecularly and mor-
phologically. Muse-derived melanocytes were pigmented,
as compared to the negative control. Furthermore, they
differentially expressed human melanocyte markers. This
evidence suggests that various skin diseases due to melano-
cyte dysfunction, including the prevalent vitiligo, could be
treated using Muse-derived melanocyte transplantations.
Muse cells and non-tumorigenicity: a scientific anomaly
The definition of pluripotency relies upon a cell’s ability to
differentiate into the three embryonic germ layers, and in
the case of stem cells, to self-renew [29]. Tumor formation
coincides with both pluripotency and self-renewal and has
emerged as a critical factor in determining the pluripotent
capacities of both ES and iPS cells [30-33]. However, as seen
in ES and iPS cells, the capacity for tripoblastic differenti-
ation and self-renewal is frequently uncontrolled, and often
materializes in teratoma formation, hindering the exploit-
ation of their pluripotency for regenerative purposes. How-
ever, innate pluripotent stem cells, including epiblast stem
cells and neoblasts present in planarians, do not form tera-
tomas in the way that ES and iPS cells do [34]. Planarians
and newts, which have the ability to regenerate amputated
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cells [35].
Despite their characterization as pluripotent stem cells,
Muse cells exhibit both low proliferative and telomerase
activities, a normal karyotype as well as asymmetric
division, and thus do not undergo tumorigenesis or tera-
toma formation when transplanted into a host organism
[24,26,27] (Figure 1). Low telomerase activity is partially
responsible for this peculiar balance [27]. Muse cells also
exhibit much lower expression of the so-called “Yamanaka
factors” in comparison with iPS cells (>105 fold decrease)
[25]. Furthermore, Muse cells exhibit a slight increase in
expression of Sox2, Nanog, Oct3/4 as compared to non-
muse cells (2–4 fold) [24,26]. Intermediate expression of
the genes that have been shown to confer pluripotency
and teratogenesis may explain how Muse cells retain their
lineage plasticity while simultaneously negating teratoma
formation.
Lin28, a RNA-binding protein gene, maintains both
pluripotency and tumorigenesis in ES and iPS cells [36,37].
Let-7, a microRNA that regulates embryonic development,
cell differentiation and tumor suppression, has the oppo-
site effect [37]. While over-expression of Let-7 blocks
Lin28 gene expression, Lin28 expression degrades Let-7,
maintaining a balance in their expression, controlling de-



























Figure 1 Non-tumorigenicity of Muse cells. (A) Embryonic stem (ES) cells
teratomas within 8 to 12 weeks, (B) Histological analysis showed that the tera
skin, (C) Muse cell-transplanted testes did not generate teratomas similar to u
normal structure even 6 months post-injection (Pictures reproduced from Pro
DOI: 10.1089/scd.2013.0473).decline over the course of embryonic development while
let-7 miRNA’s simultaneously increase, suppressing self-
renewal of undifferentiated cells and stimulating cell dif-
ferentiation. ES and iPS cells have a very high Lin28/Let7
ratio, which has been thought to play a major role in their
tumorigenic propensities [37]. In the absence of a strong
Lin28 influence, Muse cells retain their pluripotent cap-
acity [25]. Over-expression of Let-7 in Muse cells would
potentially play a critical role in inhibiting Lin28 expres-
sion, and therefore would protect these cells from tumori-
genic proliferation and teratoma formation after in vivo
transplantation.
Retaining their self-renewing ability, Muse cells do not
undergo unbridled proliferation or tumor formation
in vivo, setting them apart from ES cells. When trans-
planted into the testes of immune-deficient mice, Muse
cells did not form teratomas while ES cells formed large
teratomas within 8–10 weeks [27]. As pluripotency and
tumorigenesis have commonly been considered a pack-
aged deal, it is imperative to consider what factors allow
Muse cells to avoid tumor formation while retaining
their capacity for differentiation into all three germ
lineages.
It has been postulated that iPS cells are generated ex-
clusively from Muse cells [25]. When fibroblasts were
subjected to the Yamanaka factors, only Muse cellsTeratoma
Normal testis
infused into immunodeficient mice (SCID mice) testes, formed
toma contained muscle tissue, intestine-like structures and keratinized
ntreated testes, and (D) Testes injected with Muse cells maintained
c Natl Acad Sci USA 2010, 107: 8639–43, and Stem Cells Dev 2014
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analysis shows that classical markers of tumorigenesis,
including BCR1, CCMB1 and CCMB2, are highly ex-
pressed in iPS cells derived from Muse cells as com-
pared to naïve Muse cells [25]. In contrast, CDKN1A
and CDKN2A, involved in tumor suppression, are highly
expressed in Muse cells versus iPS cells derived from
Muse cells [25]. This may shed light on the effects of the
induction of the Yamanaka factors and their contribution
to tumorigenesis, as well as the inherent propensity for
teratoma formation in iPS cells but not Muse cells,
however further studies are required to elucidate this
distinction.
Muse cells derived from adipose tissue (Muse-AT)
We isolated Muse cells derived from adipose tissue har-
vested by lipoaspiration (Muse-AT cells) under severeFigure 2 Muse-ATs express pluripotent stem cell markers. Immunofluo
individual Muse-AT cells, express characteristic pluripotent stem cell markers, i
Comparatively, ASCs (right panel) derived from the same lipoaspirate under s
markers. Nuclei were stained with DAPI (blue). Original magnification, 600 X (Pcellular stress conditions [26]. Furthermore, Muse cells
isolated from adipose tissue can be also obtained from
commercially available human adipose stem cells (ASCs)
through SSEA-3 cell sorting [27]. Much like their
relatives derived from bone marrow aspirates and skin
fibroblasts [24], Muse-AT cells grow in suspension as
cell clusters, similar to embryoid bodies, which express
the classic pluripotency markers SSEA3, Sox2, Oct3/4,
Nanog, and TRA1-60 [24,26] (Figure 2).
Under unperturbed physiological circumstances, Muse-
AT cells reside within the adipocyte and stromal vascular
fractions [26]. Within both fractions, cross-talk between
ASCs and adipose tissue-residing macrophages (ATMs)
contributes to cell plasticity, adipogenesis and ASC for-
mation [39] (Figure 3). ASCs, ATMs and adipose immune
infiltrating cells may interact with neighboring Muse-AT
cells, affecting their lineage plasticity, adipose tissuerescence microscopy demonstrates that Muse-AT aggregates, along with
ncluding SSEA3, Oct3/4, Nanog, Sox2, and TRA-1-60 [24,26] (Figure 2).
tandard conditions [38] were negative for these pluripotent stem cell




Figure 3 Graphical depiction of different cell components present in adipose tissue. Adipose tissue is composed of adipocytes and the
stromal vascular fraction containing adipose tissue macrophages (ATMs), adipose stem cells (ASCs) and Muse-AT cells, among other cell components.
Simerman et al. Clinical and Translational Medicine 2014, 3:12 Page 5 of 8
http://www.clintransmed.com/content/3/1/12differentiation and repair, and the production and re-
cruitment of signaling molecules in times of cellular
stress [26].
Muse-AT cells differentiate into mesodermal, endoder-
mal and ectodermal embryonic germ lineages sponta-
neously, with 23%, 20% and 22% respective efficiencies
[26]. Incubated in the presence of lineage-specific media,
Muse-AT cells differentiate with 82%, 75% and 78% re-
spective efficiencies. Furthermore, Muse-AT cells exhibit
lineage-specific morphological characteristics after only
3 days in culture [26]. Immunocytochemistry studies
showed expression of markers for adipocytes, myocytes,
hepatocytes and neural cells in both naïve Muse cells and
Muse cells that had been induced to differentiation in
tissue-specific culture media [26]. For example, Muse-AT
cells demonstrated formation of lipid droplets when in-
duced to differentiate into adipocytes (Figure 4A), as well
as characteristic smooth muscle striations when induced
to differentiate into myocytes (Figure 4B) [26]. Employing
identical culture conditions used to induce ES and iPS dif-
ferentiation into hepatocytes, Muse-AT cells were also
driven to differentiate into hepatocyte-like cells (Figure 4C)
[26]. Furthermore, Muse-AT cells differentiate into neural-
like cells, forming long, finger-like projections, typical of
neurons, similar to ES and iPS cells (Figure 4D) [26].
Muse-AT cells could therefore be applied to treat muscle,liver and brain disorders without the teratogenic risk asso-
ciated with ES and iPS cells.
Genes associated with cell death and survival, embryo-
nic development, organismal development, tissue deve-
lopment, cellular assembly and organization, and cellular
function and maintenance are highly conserved, with
homologues present in numerous primordial organisms
including yeast (S. Cerevisiae), C. elegans, chlamydomonas,
T. californica, and fruit fly (Drosophila). Muse-AT cells
differentially express genes from all of the aforementioned
categories, suggesting that Muse cells may function ac-
cording to a highly conserved cellular mechanism related
to cell survival in response to severe cellular stress [40,41].
For medical and cosmetic reasons, lipoaspirate mater-
ial is routinely extracted from the human body due to its
availability, accessibility and abundance. Because adipose
tissue is present in such a high abundance within the
human body, the number of extractable Muse-AT cells is
abundant compared to that which can be extracted from
bone marrow or dermis. Muse-AT cell isolation from
lipoaspirate material is both temporally and monetarily
efficient.
Muse-AT cells and quiescence
Muse cells exist in a quiescent state under normal
physiological circumstances within the cellular niche
Figure 4 Tripoblastic characteristics of Muse-AT cells. Muse-AT cells were grown as adherent cells in the presence of (A) adipogenic medium;
the formation of adipocytes was detected using BODYI-PI-C16 which identify lipid drops present in adipocytes; (B) myogenic differentiation
medium; the formation of myocytes was detected using an anti-human MSA antibody; (C) hepatogenic differentiation medium; formation of
hepatocytes was detected using an anti-cytokeratin 7 antibody; (D) Muse-AT cells were grown for 7 days as non-adherent cells and then cultured
for an additional 7 days as adherent cells; neural-like cells were detected by immunofluorescence using an anti-human MAP2 antibody. Nuclei
were stained with DAPI (blue). Original magnification was 600X. (Pictures reproduced from PLoS One 2013, 8(6):e64752).
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their capacity for self-renewal, multiple adult stem cell
lineages have been shown to exist in a quiescent state,
including hematopoietic stem cells and epithelial stem
cells [42,43]. The mobilization of quiescent stem cells is
attributed to CXCL2, a chemokine, which functions in
stem cell homing [43]. Exposing MSCs to CXCL2 prior to
transplantation increases post-transplant stem cell survival
rates in cases of myocardial infarction [44]. In the case of
Muse-AT cells, CXCL2 is expressed 770 folds higher than
in neighboring ASCs, which could therefore explain their
genetic predisposition to cellular stress resistance [22].
CXCL2, overexpressed in cancer cells, contributes both to
cancer cell survival and malignancy. Quiescence is the
“natural” state in which Muse cells exist. On the other
hand, quiescence contributes to the maintenance of malig-
nancy in cancer stem cells in a dormant stage, susceptible
to relapse in the wake of cancer treatment [36]. The in-
ternal/external stimuli that activate Muse cells (prolonged
treatment with proteolytic enzymes, lack of nutrients, low
temperatures, hypoxia) are entirely different than those
that activate cancer stem cells (ionizing radiation, ultra-
violet radiation, chemical compounds, reactive oxygen
species, error prone DNA repair, among others).Nevertheless, Muse cells (non-tumorigenic cells) can
be converted into iPS cells (tumorigenic cells) when ex-
posed to the four “Yamanaka factors” [25].
Microarray analysis showed differential expression of
144 critical genes involved in cell death and survival (e.g.
SGK1, MDH1, ATF2, HSPA8, PDIA3, BRD1, CALM1,
NR4A2, GATA2, CDK6, NUF2, CDK6, BRC1, BUB1B
and CXCL2), suggesting that expression of these genes
could contribute to Muse-AT cell activation from quies-
cence [26]. Furthermore, Muse-AT cells over-express
ALDH1A2 (47 fold change versus ASCs) and SOD2 (41
fold change versus ASCs) which boast anti-oxidative
stress and anti-apoptotic functions [44,45]. Interestingly,
DNA repair genes are generally up-regulated in Muse-
AT cells, indicating a high capacity to resist DNA da-
mage due to cellular stress [26].
The application of stem cells in regenerative medicine
has often been impeded by a low survival rate (<3%),
when exposed to the high stress environment of the en-
graftment site, especially in cases of myocardial infarc-
tion, ischemic injury and stroke [40,46-50]. Investigators
have utilized hypoxia preconditioning (HPC), a process
in which stem cells are introduced to hypoxic conditions
for 24–48 hours prior to transplantation, to acclimatize
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nutrition, pro-inflammatory cytokines and reactive oxygen
and nitrogen species, in order to enhance post-transplan-
tation stem cell survival [51-53]. Muse cells, however, do
not require HPC or any other pre-transplantation condi-
tioning, as they are intrinsically resilient to cellular stress
[24,26]. A long-term trypsin (LTT) incubation, or proteo-
lytic digestion, was employed to isolate Muse cells from
bone marrow aspirates and skin fibroblasts [24]. Human
adipose tissue lipoaspirate material was subjected to even
more severe cellular stress conditions including long-term
exposure to the proteolytic enzyme collagenase (LTC),
serum deprivation, low temperatures and hypoxia. This, in
turn, produced a highly purified population of Muse
(Muse-AT) cells [26]. As cellular stress induction is im-
perative to Muse cell isolation, and thus intrinsic to their
activation, their capacity for survival and the ultimate
translational objective of tissue regeneration in vivo is
greater as compared to alternative stem cell populations.Conclusions
The potential application of Muse cells in regenerative
stem cell therapies is both innovative and promising.
Muse cells are inherently resistant to cellular stress, and
genetically resilient to DNA damage, supporting their
application for the investigation of age-related and dege-
nerative diseases. Moreover, because Muse cells possess a
pre-perturbation and an intrinsic propensity for quies-
cence, they may have the potential to elucidate new ave-
nues of cancer research, specifically with regards to the
mechanism behind quiescence, and malignancy [26,43].
Finally, and perhaps most thrillingly, Muse cells could be
harvested for the purposes of creating autologous stem
cell banks. Because of their differentiation capacity, Muse
cells could be utilized to regenerate any type of tissue and
thus treat neurological and immune disorders, and in-
juries to critical organs such as the heart and brain.
Furthermore, Muse-AT cells are isolated from lipoas-
pirate material which is easily accessible, abundant, and
non-invasively extracted from the human body for both
medical and cosmetic purposes. Hundreds of millions of
adipose cells can be extracted from a mere 1–2 liters of
tissue, enhancing the number of extractable Muse-AT
cells. Muse-AT cells are a promising candidate for transla-
tional application in stem cell therapy and regenerative
medicine, thus it is imperative to further investigate and
exploit their unique qualities and vast potential.
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